Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

Marijuana Company of America’s $MCOA Overview of 2017 Highlights $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:47 AM on Wednesday, January 3rd, 2018

15233 mcoa

2017 HIGHLIGHTS

  • MCOA became a fully reporting company by filing a Form 10 with the SEC in May of 2017
  • In Q1 2017, MCOA entered into a joint venture partnership with Bougainville Ventures, Inc
  • In Q3 2017, MCOA and Global Hemp Group, Inc. (CSE: GHG) (OTC: GBHPF) entered into a joint venture partnership to develop commercial hemp production and processing in New Brunswick
  • In October 2017, MCOA and GHG jointly entered into a letter of intent  with Space Cowboys, Inc.

Escondido, California–(January 3, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce its 2017 year-end review to its valued shareholders and interested parties.

Donald Steinberg, CEO of MCOA, said: I am the founder of multiple startups, including Medical Marijuana Inc. (OTC: MJNA), which has a market cap of over 300 million dollars. I am aware of the challenges and opportunities these endeavors present, and the need for a strong foundation to build upon. Having experience in the structuring, development and operations of large global marketing companies in various industries, I believe Marijuana Company of America and its subsidiary hempSMART are poised to deliver significant value to our shareholders based on the foundations and accomplishments made in the past year. 

The Company has fulfilled its promise to its shareholders by becoming an audited and fully transparent reporting company with the Securities and Exchange Commission. We are participating in the cannabis space with our leasing operation in Washington. The hempSMART team has developed a line of products that can be viewed at www.hempsmart.com. We completed joint hemp trials in New Brunswick, Canada with Global Hemp Group, Inc. in 2017, and we expect to be starting commercial production in Spring 2018. There are a number of other projects we are completing due diligence on. I am thankful to the teams at MCOA and hempSMART for their accomplishments and due diligence in working through these various projects.  We will continue to build upon the diligent work of the past year as we continue to move forward and execute our business plan.”

Updates on hempSMART Products

The Company’s wholly owned subsidiary, hempSMART, Inc., distributes industrial hemp based CBD wellness products via network marketing. In September 2017, the Company completely revamped its website and network marketing platform to provide customers and affiliates with the necessary tools needed to become successful in the expanding $1.9 Trillion Wellness Industry. The Company has successfully filed a patent application with the U.S Patent and Trademark Office for full patent protection on its proprietary CBD formulation: “hempSMART™ Brain.” Also in 2017, hempSMART released two new products: “hempSMART™ Full Spectrum Drops” (Orange, Mint, Lemon, and Strawberry) and “hempSMART™ Pain Capsules.” Several more products are in development and the Company anticipates their release in Q1 2018.

Filing Form 10 with SEC and Completing Audit

MCOA became a fully reporting company by filing a Form 10 with the SEC in May of 2017. A PCOAB registered audit firm (L & L CPAs PA) completed a two-year audit of the Company’s 2015 and 2016 financial statements. This is an integral step to qualifying the Company to uplist its trading tier with OTC Markets to the OTCQB. This is an important step in helping MCOA raise necessary capital to fund it projects and expand operations, as well as provide more transparent and reliable information to investors. Currently, the Company is in the process of preparing and filing an S-1 registration statement with the SEC in order to raise the necessary capital to fund its aggressive growth goals for 2018. Due to the inherent legal complexity of the cannabis industry, it took considerable effort to address SEC comments pertaining to disclosures of our business and corresponding products. We believe there is a great deal of shareholder value by the Company distinguishing itself from a majority of cannabis public companies that elect not to be fully reporting SEC filers.

Cultivation Joint Venture in Washington State

In Q1 2017, MCOA entered into a joint venture partnership with Bougainville Ventures, Inc. (“BV”), who plans to construct a 30,000 sq. ft. greenhouse cultivation facility in Oroville, WA. The facility will accommodate a Tier-3 production and processing I-502 tenant with years of experience in cannabis cultivation. In Q4 of 2017, MCOA completed financing of $800,000 in cash and 15 million shares of the Company’s common stock to complete the amended terms of the agreement. The delivery of the first pre-designed greenhouses, with full tracking and reporting protocols has arrived and completed construction of the six greenhouses, totaling in a one-acre footprint, is expected in Q1 2018. This joint venture project is solely for the purpose of cultivation and processing of legal marijuana within the state of Washington only and not beyond its borders. The Company will lease the turnkey property to the licensed tenant, thus acting solely as a landlord. As of December 31, 2017, the first greenhouse was purchased and in the process of being constructed.

JV with Global Hemp Group in Canada

In Q3 2017, MCOA and Global Hemp Group, Inc. (CSE: GHG) (OTC: GBHPF) entered into a joint venture partnership to develop commercial hemp production and processing in New Brunswick, Canada. MCOA and GHG have now completed the first phase of hemp trials, receiving research support from the Collége Communautaire du Nouveau Brunswick (CCNB). MCOA is granted a Right of First Refusal as the primary recipient of any raw materials produced from the project, which we expect will harvest its first commercial crop of 125 acres in Q4 2018.

MoneyTrac Technologies Investment

In July 2017, MCOA completed an investment of $250,000 into MoneyTrac Technology, Inc. (“MTT”), a subsidiary of Global Payout, Inc. (OTC: GOHE) in exchange for 15% equity position in the company, to help establish and market MTT as an alternative banking solution for the Cannabis industry. MTT currently has the ability to integrate and streamline electronic payment processing such as E-wallet, mobile applications, debit cards, and credit cards. Currently, MoneyTrac Technology has strategic partnerships with top cannabis services such as GreenRush, BlazeNow, High Grade Management Group, and PotSaver, which was a majority acquisition last October.

BeniHemp Investment

At the end of Q4, the Company announced an investment of $100,000 for a 25% equity stake in Convenient Hemp Mart, LLC’s “BeniHemp” branded products to target convenience stores for CBD product distribution. BeniHemp products will include topicals, tinctures, and edibles conveniently packaged in 1-day, 2-day, and 30-day supplies. The target market is convenience stores, smoke shops, gas stations and similar small retail businesses. The expectation is that there will be a full launch and website online in January 2018.

Space Cowboys, Inc.

In October 2017, MCOA and GHG (“the Companies”) jointly entered into a letter of intent (LOI) with Space Cowboys, Inc. (“Space Cowboys“). Pursuant to the terms of the LOI, the Companies intended to invest US$2.5 Million in exchange for a 25% equity interest in Space Cowboys. However, the Companies are unable to complete due diligence and will not be moving forward with this project.

Joint Venture in Adelanto, CA

In March, MCOA entered into a joint venture agreement with GateC Research Inc. (“GCR”) for the purpose of developing a turnkey cultivation facility in Adelanto, California for leasing to GCR which owns a local permit for cultivation. GCR and MCOA are in the process of identifying and securing property to facilitate the project. MCOA will invest cash and stock to complete the agreement. With the recent legalization of cannabis for recreational use on January 1, 2018 in California, MCOA expects to focus its attention on actualizing this opportunity in California. This JV project is solely for the purpose of cultivation of legal marijuana within the state of California and not beyond its borders. The Company will act solely as a landlord in this JV.

Investor Relations

Also in 2017, MCOA engaged NetworkNewsWire (“NNW”) for the Company’s corporate communication solutions. NNW is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. NNW’s strategies help public and private organizations find their voice and build market visibility. As part of the Client-Partner relationship with MCOA, NNW will leverage its investor-based distribution network of over 5,000 key syndication outlets, various newsletters, social media channels, blogs, and other outreach tools to generate greater brand awareness for the Company.

About Marijuana Company of America, Inc.
MCOA
is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About MoneyTrac Technology
MoneyTrac Technology, Inc. is a pioneer in offering a full-service solution for alternative banking and electronic financial solutions and provides all aspects of financial technology including E-Wallet and mobile apps services for businesses and companies in various “high-risk” industries. MoneyTrac’s technology platform allows for its clients to access their financial information from anywhere in the world, in addition to providing tracking and compliance to help them manage and control the flow of all revenue through their business.

About Global Hemp Group Inc.
Global Hemp Group (“GHG”) is a publicly traded company founded in 2012, headquartered in British Columbia, Canada with base operations in Montreal and Southern California. The Company is focused on the production and processing of hemp, and collaboration with companies that will enable GHG to develop and implement the Hemp Agro-Industrial Zone concept. Through partnerships, joint ventures and acquisitions, the Company will capture cash flow, revenues, and establish a greater collective valuation.

About Bougainville Ventures, Inc.
Bougainville Ventures Inc. is in the business of investing in high grow companies and industries that lease land, equipment and other growing infrastructure to licensed marijuana producers and luxury crop growers. Bougainville itself is not a licensed marijuana grower or retailer but instead focuses on providing capital to companies which act as landlords and equipment leasing companies to licensed marijuana producers and luxury crop growers. The Company is in the process of being listed on the CSE in Canada.

Forward Looking Statements
This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Tetra Bio-Pharma $TBP.ca Enters into Agreement to Acquire Remaining 20% Interest in Phytopain Pharma Subsidiary $AERO $CBDS $CGRW $APH.ca $GBLX #CBD #Marijuana

Posted by AGORACOM-JC at 9:13 AM on Tuesday, January 2nd, 2018

Logo tetrabiopharma rgb web

  • Announced that it has entered into a share purchase agreement  with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation
  • Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc.

OTTAWA, ONTARIO–(Jan. 2, 2018) Tetra – Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development, today announced that it has entered into a share purchase agreement (the “Purchase Agreement“) with entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation (collectively, the “Vendors“).

Under the terms of the Purchase Agreement, Tetra will acquire from the Vendors all of the remaining issued and outstanding common shares of Tetra’s subsidiary, Phytopain Pharma Inc. (“PPP“), currently held by the Vendors (representing 20% of the issued and outstanding shares of PPP) for an aggregate purchase price (the “Purchase Price“) of $12,425,089 (the “Transaction“). Upon completion of the Transaction, PPP will become a wholly-owned subsidiary of Tetra.

“Upon completion, this transaction will be a significant milestone for Tetra Bio-Pharma and all our stakeholders,” said Bernard Fortier, Tetra’s CEO.

“The two selling shareholders – our Chairman and our Chief Scientific Officer – are both committed to the long-term success of Tetra as evidenced by their agreement to accept shares in Tetra in lieu of an all- cash transaction. As well, a percentage of those shares are going to be released once certain key milestones for the company have been reached,” he said.

“This transaction will allow Tetra to gain 100% control of Phytopain Pharma, a key asset in the development of our pipeline of cannabinoid-based drugs and gives our company full flexibility to enter into other partnerships or agreements in the future.”

The Transaction is subject to customary closing conditions including, but not limited to, approval of the TSX Venture Exchange (“TSXV“) and any other approval that may be required by the TSXV.

The Transaction

Under the terms of the Purchase Agreement, the Purchase Price for the Transaction is comprised of the following:

  • Cash: An aggregate cash payment of $248,000 (the “Cash Payment“). Under the terms of the Purchase Agreement, the Cash Payment is payable in escrow as of the signature of the Purchase Agreement and has been paid to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV. In addition, Tetra has agreed to pay the Vendors, immediately upon signature of the Purchase Agreement, a non-refundable amount of $200,000, payable out of the funds available for the Cash Payment, to induce the Vendors to provide an exclusivity of negotiation to the Purchaser for the Transaction.
  • Promissory Notes: Promissory notes issued by Tetra to the Vendors in an aggregate principal amount of $2,236,696 (the “Notes“), which Notes are payable in accordance with a specified milestone schedule as described in the Purchase Agreement. Pursuant to the terms of the Purchase Agreement, the Notes have been delivered to the Vendors’ legal counsel in trust for the Vendors pending receipt of approval for the Transaction from the TSXV.
  • Tetra Shares: Common shares of Tetra (“Common Shares“) will be issued to the Vendors as follows:
    • Upon completion of the Transaction, an aggregate of 2,485,218 Common Shares will be issued to the Vendors.
    • Upon completion of the Transaction, 7,455,653 Common Shares will be issued to
      Computershare Trust Company of Canada, as escrow agent (the “Escrow Agent“), to be held in escrow and released by the Escrow Agent under the terms and conditions set forth in the Purchase Agreement and the terms and conditions of an escrow agreement to be executed at closing by the Vendors, the Corporation and the Escrow Agent.

The Vendors under the Purchase Agreement are entities controlled by André Rancourt, Chairman of the Board of Directors of the Corporation, and Guy Chamberland, Chief Scientific Officer of the Corporation and are therefore considered “non-arm’s length parties” under the rules of the TSXV. Mr. Rancourt and Mr. Chamberland have properly disclosed their respective interest in the Transaction to the board of directors of the Corporation.

The Transaction constitutes a “related party transaction” within the meaning of Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”). While MI 61-101 would generally subject the transaction to minority shareholder approval and formal valuation requirements, the Corporation will avail itself of the exemptions applicable under Section 5.5(a) of MI 61- 101.

Mr. Rancourt currently has ownership or direction and control over (i) an aggregate of 465,000 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 0.37% of the issued and outstanding Common Shares on a non- diluted basis and approximately 4.66% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Rancourt are released to Mr. Rancourt or an affiliate of Mr. Rancourt in accordance with the Purchase Agreement, Mr. Rancourt would then have ownership or direction and control over (i) 5,435,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.20% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.17% of the issued and outstanding Common Shares.

Mr. Chamberland currently has ownership or direction and control over (i) an aggregate of 1,250,000 Common Shares, (ii) 350,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 1.00% of the issued and outstanding Common Shares on a non-diluted basis and approximately 4.32% of the issued and outstanding Common Shares on a partially diluted basis. Further to the completion of the Transaction, and assuming that all of the Common Shares issued in escrow and allotted to Mr. Chamberland are released to Mr. Chamberland or an affiliate of Mr. Chamberland in accordance with the Purchase Agreement, Mr. Chamberland would then have ownership or direction and control over (i) 6,220,436 Common Shares, (ii) 1,600,000 options to acquire Common Shares and (iii) 4,000,000 Common Share purchase warrants, representing approximately 4.78% of the issued and outstanding Common Shares on a non-diluted basis and approximately 8.70% of the issued and outstanding Common Shares.

Each of Mr. Rancourt and Mr. Chamberland proposes to acquire the common shares for investment purposes, and has no current intention to increase his beneficial ownership of, or control or direction over, securities of Tetra. These investments will be reviewed on a continuing basis and their holdings may be increased or decreased in the future.

The Transaction is subject to customary conditions including, but not limited to, approval of the TSXV. The Transaction has been unanimously approved by Tetra’s board of directors (with André Rancourt abstaining from voting) and Tetra anticipates that the Transaction will be completed in the first quarter of 2018.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid- based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products. More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Corporation, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princepsproduct offering and inhalation device; guidance on expected sales volumes associated with the Rx Princepsproduct offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Bernard Fortier, MBA
Chief Executive Officer
(514) 360-8040 Ext. 206
bernard.fortier@tetrabiopharma.com
www.tetrabiopharma.com

Aurora $ACB.ca and Namaste $N.ca $NXTTF to Complete Strategic Private-Label Software and Patient Referral Agreements $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 7:19 AM on Tuesday, January 2nd, 2018

Nlogo

  • Namaste will provide CanvasRx with a customized, CanvasRx-branded version of NamasteMD
  • Namaste will provide CanvasRx with a two-year exclusivity period for the private label version of NamsteMD.com in Canada

EDMONTON and VANCOUVER, Jan. 2, 2018 – Aurora Cannabis Inc. (the “Company” or “Aurora”) (TSX: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Namaste Technologies Inc. (“Namaste”) (CSE: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) today announced the signing of a binding term sheet towards a final Private-Label Software Agreement (“Private Label Agreement”), whereby Namaste will provide Aurora’s wholly-owned subsidiary, CanvasRx Inc. (“CanvasRx”) with a customized version of Namaste’s patient acquisition tool, NamasteMD.com (“NamasteMD”),  as well as desktop and mobile applications for Google Android and Apple iOS platforms. The companies have 30 days to complete a final agreement.

Private Label Agreement

NamasteMD is an online telemedicine platform for patient consultation and registration, bringing together Namaste`s tested technology platform, including certain proprietary authentication technologies, as well as consultation, education and medical document issuance processes. Under the terms of the Private Label Agreement:

  • Namaste will provide CanvasRx with a customized, CanvasRx-branded version of NamasteMD
  • Namaste will provide CanvasRx with a two-year exclusivity period for the private label version of NamsteMD.com in Canada
  • Namaste will initially provide the application for both the Google Android and Apple iOS platforms
  • CanvasRx will require their own doctors and/or nurse practitioners to operate the platform
  • Commercial terms of the agreement are not disclosed
  • In consideration of Aurora’s assistance for the future optimization of NamasteMD, Namaste has issued Aurora 500,000 stock options, exercisable at $3.35 per common share for 48 months, vesting quarterly over 12 months.

Support Services Agreement

In addition, the companies have also signed a non-binding, non-exclusive Letter of Intent to complete a final Consultation & Support Services Agreement (“Consultation Agreement”), whereby Namaste will provide patient referral services to Aurora, where applicable under Canada’s Access to Cannabis for Medical Purposes (“ACMPR”) regulations. Under the terms of the Consultation Agreement:

  • Namaste shall provide certain patient-focused education and strain selection services, as well as assistance in preparing the requisite paperwork (Medical Documentation) for registering patients with Aurora
  • The Agreement is non-exclusive for a one-year term
  • Namaste shall provide the services under the agreement on preferential terms to Aurora
  • Commercial terms of the Consultation Agreement are not disclosed

The agreements further strengthen the strategic ties between the two companies, who already collaborate on eCommerce (sale of Namaste-sourced, curated selection of vaporizers through Aurora website, utilizing Namaste’s technology platform), and the distribution of BC Northern Lights products. Once completed, the new agreements will provide Namaste with recurring revenues through the private label platform, while Aurora will be the only licensed producer able to offer Namaste`s streamlined online patient acquisition platform under its own (CanvasRx) brand.

Management Commentary

“NamasteMD provides an innovative and efficient extension to our industry-leading in-person cannabis counseling and education services provided through CanvasRx,” said Terry Booth, CEO. “The new platform will enable us to extend our industry leading patient care to areas where we currently have no physical presence. This will allow us to leverage the strength of both the CanvasRx and Aurora brands, without having to commit to substantial investments in brick and mortar facilities. Namaste is a trusted partner with whom we already successfully collaborate on two promising initiatives, and we look forward to extending our partnership based on innovation and customer care excellence.”

Sean Dollinger, President and CEO of Namaste added, “We are thrilled to have Aurora, the industry’s most innovative and dynamic Licensed Producer, as our preferred strategic partner. Our drive to innovate meets the cannabis industry`s need for reliable technological solutions to improve operational efficiencies and expand the customer experience. We are very proud to be aligned with Aurora’s team, and look forward to executing on our ongoing collaboration.”

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as “Aurora Mountain”, a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island, and is currently constructing an 800,000 square foot production facility, known as “Aurora Sky”, at the Edmonton International Airport, as well as is completing a fourth facility in Lachute, Quebec through its wholly owned subsidiary Aurora Larssen Projects Ltd.

In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora’s common shares trade on the TSX under the symbol “ACB”.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany, and has opened new supply channels into emerging markets, including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Boards of Directors

Terry Booth

Sean Dollinger

Chief Executive Officer

Chief Executive Officer

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Aurora and Namaste are under no obligation, and expressly disclaim any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX or CSE, nor their Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange and CSE) accept responsibility for the adequacy or accuracy of this release.

World Health Group: Pot’s #CBD Has Health Benefits #Marijuana $MCOA $N.ca $TBP.ca $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 4:25 PM on Tuesday, December 19th, 2017
  • Compound found in the cannabis plant is not harmful, has health benefits, and does not have abuse potential, experts at the World Health Organization say.
  • WHO’s Expert Committee on Drug Dependence focused on cannabidiol, or CBD, one of the naturally occurring cannabinoids found in cannabis plants

After reviewing evidence from animal and human studies, the committee concludes that “In humans, CBD exhibits no effects indicative of any abuse or dependence potential.”

Slideshow: Medical Marijuana

1/10

What Is Medical Marijuana?

Medical marijuana is any part of the marijuana plant that you use to treat health problems. People use it to get relief from their symptoms, not to try to get high.

Most marijuana that’s sold legally as medicine has the same ingredients as the kind that people use for pleasure. But some medical marijuana is specially grown to have less of the chemicals that cause feelings of euphoria.

The experts also say that CBD might be able to treat epilepsy (where most research has focused), although results are mixed. Other conditions it might treat are Alzheimer’s disease, Parkinson’s, anxiety, depression, and other maladies. CBD may ease inflammation, provide antioxidants, and relieve pain.

Based on its research, the committee concluded that current information does not call for scheduling of the drug. In the U.S., CBD is a Schedule 1 controlled substance. These are defined as drugs with no medical use and likely to be abused.

Twenty-nine states and Washington, D.C., have legalized the use of marijuana for recreational or medicinal purposes. Other states, including Georgia, have legalized the possession of CBD to treat specific disorders.

It remains a federal crime, however, to have or sell any form of marijuana, including CBD. Despite those federal regulations, CBD is an ingredient in popular products sold over the counter as oils, extracts, supplements, and gum to treat many ailments.

CBD usually is given as a capsule or dissolved in liquid to be taken orally, under the tongue, or as a nasal spray. CBD does not produce the high that another cannabinoid — tetrahydrocannabinol (THC) — does, experts say. In fact, CBD appears to have effects opposite of THC.

The WHO announcement drew a positive response from marijuana advocates and criticism from those who don’t want it to be legal.

The experts produced the report in November, while the WHO announced its conclusions this week. In May, the committee will study cannabis and cannabis-related substances more fully.

Other major studies have shown marijuana and its products can relieve pain, nausea related to cancer treatment, and multiple sclerosis-related muscle spasms. But using cannabis has well-known short-term and long-term health effects, such as learning and coordination problems.

Because federal law makes it a crime to have marijuana and CBD, researchers must pass strict government scrutiny just to study its usefulness.

DEA View of CBD

The conclusion of the WHO flies in the face of the view of the U.S. Drug Enforcement Administration (DEA). It says that CBD must be treated the same as THC and other cannabinoids from a cannabis plant, and it should remain a Schedule I drug.

NORML Response

Marijuana advocates applauded the WHO’s conclusion. “It was terrific to see WHO acknowledge what other scientific research has already stated,” says Justin Strekal, political director of the National Organization for the Reform of Marijuana Laws (NORML).

In an email statement, he adds: “While we are pleased to see the WHO finally acknowledge that absurdity of international restrictions, the continued domestic classification and criminalization of cannabidiol as a Schedule I controlled substance is out of step with both available science and common sense. It is yet another example of the U.S. government placing ideology over evidence when it comes to issues related to the cannabis plant.”

CALM Response

Scott Chipman, Southern California chairman of Citizens Against Legalizing Marijuana (CALM), took issue with the report.

“We need to maintain a strict scientific perspective and protocols when it comes to new drugs,” he says. “We need double-blind studies related to marijuana and all components, research on the harms versus the benefits, identification of the side effects and specific ailments identified through these studies — even for CBD,” he says.

He says some ongoing drug studies of CBD do show promise in treating seizure disorders, but he also sees potential problems with the drugs, along with concerns about contamination and other potential harms with over-the-counter products.

Source: https://www.webmd.com/a-to-z-guides/news/20171215/world-health-group-pots-cbd-has-health-benefits

Namaste Announces LOI With Supreme Pharmaceuticals $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by Er at 7:30 AM on Monday, December 18th, 2017

 

  • Supreme will supply CannMart ( Namaste ) with a premium range of high quality dried cannabis flower which will be offered in the Company’s medical marketplace
  • Namaste has committed to work with Supreme as a preferred vendor as related to possible branded partnerships
  • The LOI represents further progress for Namaste in securing this supply agreement with one of Canada’s leading producers of premium quality cannabis

 

Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) is pleased to announce a Letter of Intent (the “LOI”) with Supreme Pharmaceuticals Inc. (“Supreme”) (TSXV:FIRE) (OTCMKTS:SPRWF). The LOI, signed by Supreme’s wholly owned subsidiary, 7ACRES, and Namaste’s wholly owned subsidiary, Cannmart Inc. (“CannMart”), provides that Supreme will supply CannMart with a premium range of high quality dried cannabis flower which will be offered in the Company’s medical marketplace. Supreme is focused on producing high quality cannabis through a commitment to carefully curated genetics, quality focused cultivation practices and a post-harvest process that includes a 14-day whole plant drying process and hand finishing of each flower.  Under the terms of the LOI, Namaste has committed to work with Supreme as a preferred vendor as related to possible branded partnerships, in addition to supply for Namaste’s in-house branded medical cannabis.  All Supreme cannabis will bear the 7ACRES producer’s mark. Namaste believes that Supreme’s Business to Business (B2B) distribution model fits well with Namaste’s focus on becoming Canada’s leading online retailer for medical cannabis.

Other terms of the LOI include:

  • Purchase orders to be submitted accompanied by terms and conditions governing the purchase and sale of medical cannabis in accordance with Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”)
  • All products sold by 7ACRES to CannMart will be in accordance with ACMPR, 7ACRES Standard Operating Procedures (SOP) and GMP Practices
  • 7ACRES will provide all product descriptions and photography to be used with respect to the sale of 7ACRES products through CannMart
  • CannMart will display 7ACRES trade-mark on all packaging in connection with the sale of any 7ACRES products through CannMart’s website
  • 7ACRES shall be CannMart’s preferred supplier of premium dried cannabis flowers as it relates to celebrity endorsements in partnership with CannMart and Namaste
  • All shipping costs shall be borne by CannMart

The LOI represents further progress for Namaste in securing this supply agreement with one of Canada’s leading producers of premium quality cannabis. Namaste will focus on offering the largest variety of medical cannabis products, sourced from both domestic and international licensed producers. Management feels strongly that the Company’s relationship with Supreme will offer great value with Supreme’s focus on cultivation while Namaste intends to become Canada’s largest online retailer for medical cannabis through the implementation of its telemedicine application, NamasteMD, built as a patient acquisition tool for Namaste to leverage its growing database of Canadian site visitors and offering an extensive variety of medical cannabis products to CannMart’s patients.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “We are very pleased to be working with Supreme, who we believe to be one of the top Canadian producers of premium quality cannabis. Our goal is to create an online marketplace for our patients that will offer a variety of products sourced from various licensed producers in Canada and overseas. We believe that our relationship with Supreme will be of significant value as their business model fits well with ours. Thanks to Supreme’s management team for their support and we look forward to launching medical cannabis sales through CannMart in the early new year.”

About Namaste Technologies Inc. 
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastevapes.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.everyonedoesit.com

www.everyonedoesit.co.uk

Marijuana Company of America $MCOA Launches New hempSMART(TM) Pain Product $MJNA $GRNH $LXRP

Posted by Er at 8:34 AM on Thursday, December 14th, 2017

 

 

  • Announces the launch of its new personal care product: hempSMART™ Pain.
  • HempSMART Pain Capsules are formulated with 10mg of Full Spectrum, non-psychoactive Cannabidiol (CBD)

 

Escondido, California — (December 14, 2017) – MARIJUANA COMPANY OF AMERICA (“MCOA” or the “Company”) (OTC: MCOA), an innovative hemp and cannabis company, through its wholly own subsidiary hempSMART™, Inc., announced the launch of its new personal care product: hempSMART™ Pain.

 

HempSMART Pain Capsules are formulated with 10mg of Full Spectrum, non-psychoactive Cannabidiol (CBD) per serving, derived from industrial hemp as the core ingredient, which along with a proprietary blend of other natural ingredients, delivers an all-natural formulation for the temporary relief of minor pain associated with physical activity.

 

Once again, “HempSMART demonstrated its commitment to formulating a safe and synergistic natural personal care product. The hempSMART Pain formula harnesses the natural power of premium CBD, CBG and active terpenes derived from industrial hemp, combined with complimentary botanicals. Our team is focused on the development of premium personal care products for our customers,” said Paula Vetter member of hempSMART’s product development team.

 

“Creating a successful, growing company in our marketplace of direct sales and network marketing depends on delivering products that people need and that make a difference in their lives. The newest addition to the product line, hempSMART Pain was designed and formulated with these goals as the focus. hempSMART Affiliates now have a unique, powerful message to share with potential consumers that could generate new sales for their personal hempSMART businesses, as well as stimulate growth for the company,” commented Tim Altvater, head of affiliate marketing.

 

The CEO of MCOA Donald Steinberg added, “HempSMART Pain adds to our expanding product line. Our formulations are created by the hempSMART product development team to provide our customers with all natural products that contain CBD and other cannabinoids.”

 

About Marijuana Company of America, Inc.
MCOA is a corporation engaged in business including, but not limited to: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

 

About Our hempSMART Products Containing CBD

The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

 

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

 

For more information, please visit the Company’s websites at:

 

MarijuanaCompanyofAmerica.com

hempSMART.com

NewtworkNewsWire/MCOA

Tetra Bio-Pharma $TBP.ca Opens the Market $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 2:31 PM on Wednesday, December 6th, 2017

Logo tetrabiopharma rgb web

  • Bernard Fortier, CEO, Tetra Bio-Pharma Inc. (TBP), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market

TORONTO, Dec. 5, 2017 – Bernard Fortier, CEO, Tetra Bio-Pharma Inc. (TBP), joined Tim Babcock, Director, Listed Issuer Services, TSX Venture Exchange, to open the market. Tetra Bio-Pharma biopharmaceutical company that is engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements. Tetra Bio-Pharma Inc. commenced trading on TSX Venture Exchange on August 16, 2017.

SOURCE TMX Group Limited

Aphria $APH.ca to supply medical marijuana to Shoppers Drug Mart $N.ca $TBP.ca $MCOA

Posted by AGORACOM-JC at 1:19 PM on Tuesday, December 5th, 2017
  • Aphria Inc struck a deal to sell medical marijuana to Shoppers Drug Mart, Canada’s largest pharmacy chain
  • “Subject to Health Canada’s approval of Shoppers Drug Mart’s application to be a licensed producer, under the terms of the agreement the Company will supply Shoppers Drug Mart with Aphria-branded medical cannabis products,” a release from Aphria said. “It is expected the products will be sold online, as Canadian regulations currently restrict the sale of medical cannabis in retail pharmacies.”

Shoppers, or its parent company, Loblaw Companies Ltd., have not been issued a licence to dispense cannabis yet, according to Health Canada’s list of companies registered to grow and sell medical marijuana. It was reported in November that Shoppers was searching for someone to serve as the pharmacy chain’s medical marijuana brand manager.

Vic Neufeld, chief executive of of Aphria, said his company had a five-year agreement with Shoppers as its “first and primary supplier,” and that every year of the deal included “minimum requirements on volumes that they must purchase from us for them to maintain the following year’s exclusivity.”

Based on the terms of the agreement, specific financial terms would not be disclosed, he said.

“This stems from our long-held belief that pharmacies can, and should, play an important role in the safe and secure distribution of medical cannabis in Canada,” Neufeld added on a conference call with analysts. “It gives Aphria a huge, huge lift when it comes to the shareholder value.”

Trading of Aphria shares was halted Monday afternoon, with the company’s stock price closing up 1.93 per cent, at $11.62. Shares of the greenhouse grower are up nearly 86 per cent for the year.

The supply agreement between Aphria and Shoppers has been reached approximately seven months out from Canada’s July 2018 target date for the legalization of recreational cannabis. It also follows Saskatchewan-based medical marijuana company CanniMed Therapeutics Inc. becoming the first licensed producer to sign a deal with a national pharmacy chain when it signed a letter of intent with PharmaChoice in March of this year.

Neufeld said that during the “many months” of conversations with Shoppers, they had only discussed medical marijuana sales, not recreational.

Neufeld also said the form of “exclusivity” Aphria had given Shoppers does not restrict the pharmacy from considering “other forms of intake products, medical devices by way of example.”

“However, there is an understanding that should we be able to service their needs we would be given an opportunity to bid on it,” Neufeld added.

According to Aphria’s most recent results, for the quarter ended Aug. 31, the company reported net income of $15 million and a 15 per cent increase in sales, to 852 kilograms or kilograms equivalent of cannabis.

“For a period of time, we will not engage in any other conversations or business transactions with other national pharmacy banners in excess of a certain size,” Neufeld said. “Have we excluded certain banners? Yes, however, for us it was very important to get Canada’s leading banner in alignment with the Aphria business model, and so that’s what we agreed to.”

gzochodne@nationalpost.com
Twitter: @geoffzochodne

Source: http://business.financialpost.com/commodities/ontario-cannabis-company-aphria-to-supply-medical-marijuana-to-shoppers-drug-mart

Namaste $N.ca Announces Non-Binding Letter of Intent With O Cannabis Clinic for Management Services $ATT.ca $ABCN.ca $ACG.ca $ACB

Posted by AGORACOM-JC at 8:44 AM on Tuesday, December 5th, 2017

Nlogo

  • LOI represents a major milestone for Namaste in the expansion of its platform into medical cannabis sales using the Company’s innovative telemedicine application, and will provide an incredibly efficient platform for patient consultations and medical documentation issuance

VANCOUVER, British Columbia, Dec. 05, 2017 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (OTCQB:NXTTF) (FRANKFURT:M5BQ) is pleased to announce that it has signed an non-binding letter of intent (“LOI”)  with O Cannabis We Stand On Guard For Thee (“O Cannabis”) under which O Cannabis will provide patient consultation services to Namaste’s wholly owned subsidiary, NamasteMD Inc. (“NamasteMD”). Pursuant to the LOI, O Cannabis will provide management services to NamasteMD that will include patient consultations, education, strain recommendations and medical document issuance to qualified patients under the guidance of nurse practitioners. In addition to these services, O Cannabis will also be offering a select range of Namaste’s vaporizer hardware in their online platform.

This LOI represents a major milestone for Namaste in the expansion of its platform into medical cannabis sales using the Company’s innovative telemedicine application, and will provide an incredibly efficient platform for patient consultations and medical documentation issuance. NamasteMD customers will have the ability to connect to Namaste’s e-commerce platform through Namaste’s wholly owned subsidiary, Cannmart Inc. (“CannMart”), which will provide patients with an online marketplace for medical cannabis products, including strains sourced from both domestic and international licensed producers. CannMart is a late stage applicant for a “Sales Only License” under the Canadian Access to Cannabis for Medical Purposes Regulations (“ACMPR”) program. Namaste’s goal is to become Canada’s leading medical cannabis online retailer by leveraging its existing consumer base, along with utilizing its advanced expertise in e-commerce. In doing so, Namaste believes it can successfully convert and on-board patients at an accelerated growth rate and offer the best quality of care for its patients. Namaste believes that with its aggressive growth strategy and the implementation of NamasteMD, it will be able to accumulate a minimum of 18,200 patients within the first calendar year of operations. This figure is based on Namaste’s current site traffic of 1,000 unique visitors per day with a 5% conversion rate, which would generate 350 patients per week. Namaste expects each patient acquisition to cost on average $60 per patient, based on the terms of the LOI, which is currently lower than any industry standard for medical patients.

About O Cannabis
O Cannabis offers affordable medical cannabis telemedicine appointments to patients across Canada, allowing timely access to quality medicine in remote and under-serviced regions; from Yukon to Newfoundland and everywhere in between. O Cannabis has built a name for themselves by offering unparalleled patient education and industry leading follow up care. O Cannabis patients report their appreciation for the easy and fun telemedicine experience, O Cannabis’ streamlined approach to medical document issuance and the exceptional care patients receive at each step of their medical cannabis journey.

Terms of the LOI
Under the terms of the LOI, the O Cannabis management team will be responsible for the general operation of NamasteMD’s platform and will provide the following services:

  • Patient Qualification
  • Patient Onboarding
  • Education
  • Recommendations (strains and dosages)
  • Follow-up Care
  • Medical Documents
  • Self-titration Training
  • Maintaining 75% patient retention rates

In return for these services, Namaste will pay O Cannabis as follows:

  • CAD $60 for each patient approval, being a patient consultation resulting in the issuance of a prescription for medical cannabis
  • 50% of the net profit for “platinum” packages, as will be outlined in the definitive agreement
  • 5% of the gross revenue collected for patients where medical cannabis is sourced from local licensed producers
  • 10% of the gross revenue collected for patients where medical cannabis is sourced from international licensed producers
  • 15% of the gross revenue collected through the sale of Namaste’s vaporizers and cannabis ancillary products, which O Cannabis will add to its website
  • The issuance of 15,000 common share stock options to the O Cannabis management team

Closing of the proposed definitive agreement will be contingent on negotiation and execution of definitive documentation containing standard terms, representations and warranties and indemnities for an agreement of this nature, approval of the agreement by each party’s respective board of directors and shareholders, if applicable, and by the Canadian Securities Exchange, if applicable.

NamasteMD is an innovative application that connects patients with medical practitioners through a secure video conference call and incorporates industry-leading facial recognition technology, including instant age and identity verification using data feeds linked to federal databases.  The O Cannabis management team is a highly trained group of medical professionals that offer industry leading care for their patients. Through the NamasteMD platform, patients will be offered a variety of packages that will include both free and paid options. Once a patient receives a medical document, they will have access to purchase directly from CannMart’s medical cannabis marketplace. The Company expects full launch of NamasteMD, including the app for both Apple and Android platforms, to be in operation and accepting patients as soon as December 15, 2017.

Management Commentary
Sean Dollinger, President and CEO of Namaste comments: “With many of these exciting initiatives now in place, Namaste believes it has successfully created the necessary infrastructure to become a leader in medical cannabis sales in Canada. In addition to Canada, Namaste believes this infrastructure can be easily implemented into other progressive jurisdictions where medical cannabis legislation is in place, and fully intends on exploiting all markets where Namaste has existing operations and market presence. Our goal now is to focus heavily on patient acquisition through our existing database of consumers and to accelerate growth through our e-commerce platform.”

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, US, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: info@namastevapes.com

Further information on the Company and its products can be accessed through the links below:
www.namastetechnologies.com
www.namastevaporizers.com
www.namastevaporizers.co.uk
www.everyonedoesit.com
www.everyonedoesit.co.uk

FORWARD LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

(more…)

Canadian #Marijuana awards show lights up with first-ever gala #MMJ $TBP.ca $N.ca $MCOA

Posted by AGORACOM-JC at 10:48 AM on Thursday, November 30th, 2017
  • You know marijuana is going mainstream when the list of attendees who reserved tables reads like a who’s who of Canada’s haze of law and accounting firms, including Torys LLP, Dentons, Cassels Brock & Blackwell LLP, Bennett Jones LLP, investment dealer Eight Capital and accounting giants KPMG and MNP
By Lisa WrightBusiness Reporter
Wed., Nov. 29, 2017

What do you do if you’re a budding awards show trying to create a buzz around Canada’s $8.7-billion cannabis market?

First you weed out the best producers from the very large crop of products out there. Then you book a swanky joint and roll out the red carpet for business types looking to get in on the potential pot of gold surrounding legalization next summer.

The CEO of Lift Co., the online marketplace for the medical marijuana industry that is holding the event, says it was high time for a grass gala to highlight the fourth annual Canadian Cannabis Awards – previously held only online – in an effort to add some legitimacy to the often stigmatized cannabis community.

“It’s really going to be a mini Oscars” of pot, said Matei Olaru of the awards show being held Thursday night at the historic Carlu at College Park.

You know marijuana is going mainstream when the list of attendees who reserved tables reads like a who’s who of Canada’s haze of law and accounting firms, including Torys LLP, Dentons, Cassels Brock & Blackwell LLP, Bennett Jones LLP, investment dealer Eight Capital and accounting giants KPMG and MNP.

“These are recognizable names excited to be associated publicly with the industry,” said Olaru.

“The industry has matured enough and there are enough players, so it’s the right time for this,” he added.

In fact they will hand out a whopping 75 awards to producers and numerous other players in the marijuana business during an evening of cocktails and plenty of munchies over a sit-down dinner. The laughs will officially be provided by famed comedian twins The Lucas Brothers of 22 Jump Street and Netflix fame, who will be performing standup before the after party.

Categories range from the traditional — employer of the year, startup of the year, innovator of the year, deal of the year and even lifetime achievement award — to the offbeat, including the best in show of vape lounges, cannabis chefs, desktop and portable vaporizers, top testing lab and best home growing box.

“It’s a way to showcase those achievements,” said Olaru, whose mission is to demystify the continued confusion around the medical marijuana market as it grows like a weed.

For instance pot smoking rapper Snoop Dogg recently partnered with Canadian licensed producer Tweed, which is nominated in multiple categories.

Another sign that legalization is around the corner is Lift landing official support this week from MADD Canada as it develops Canada’s first retail training certification program for frontline staff at cannabis retailers who will have legal storefronts as of July 2018.

“Our experience with alcohol sales has shown that having comprehensive training and responsible service guidelines for front-line staff is crucial to reducing alcohol-related harms, including impaired driving,” says MADD Canada chief executive officer Andrew Murie.

“The same will be true of cannabis retail sales. MADD Canada is pleased to partner with a leader like Lift and support this program, which will ensure that all those involved in the retail sales of cannabis are well-trained about the products, about safe usage guidelines and about social responsibility principles,” he said in a release.

Source: https://www.thestar.com/business/2017/11/29/canadian-marijuana-awards-show-lights-up-with-first-ever-gala.html